Vontobel Holding’s MacroGenics MGNX Stock Holding History

Vontobel Holding’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-387,001	Closed	-$1.8M	–	1139
2023 Q3	$1.8M	Buy	387,001 +34,504	+10%	+$172K	0.02%	448
2023 Q2	$1.89M	Buy	+352,497	New	+$2.17M	0.02%	452
2023 Q1	–	Sell	-200,220	Closed	-$1.34M	–	1113
2022 Q4	$1.34M	Buy	+200,220	New	+$1.1M	0.01%	504

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vontobel Holding's MGNX Position: Q4 2023 in Review

Vontobel Holding sold out of MacroGenics (MGNX) in Q4 2023, closing a stake of 387,001 shares — an estimated $1.8M sold.

Vontobel Holding first reported a position in MGNX in Q4 2022 and held it in 3 quarters. The position peaked at $1.89M in Q2 2023. 142 funds tracked by Wall St. Rank hold MGNX as of Q4 2023.

Vontobel Holding reported no remaining MacroGenics position as of Q4 2023 after selling out during the quarter.
Vontobel Holding sold 387,001 MacroGenics shares in Q4 2023, an estimated $1.8M.
Vontobel Holding first reported a position in MacroGenics in Q4 2022 and held it in 3 quarters.
Vontobel Holding's MacroGenics position peaked at $1.89M in Q2 2023.
142 funds tracked by Wall St. Rank held MacroGenics as of Q4 2023.

Based on Vontobel Holding's 13F filing for Q4 2023, filed 30 Jan 2024.